Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Merck & Co., Inc. (MRK : NYSE)
 
 • Company Description   
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Number of Employees: 68,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $93.55 Daily Weekly Monthly
20 Day Moving Average: 12,638,675 shares
Shares Outstanding: 2,528.80 (millions)
Market Capitalization: $236,569.73 (millions)
Beta: 0.37
52 Week High: $94.56
52 Week Low: $70.89
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 10.59% 21.09%
12 Week 22.58% 37.76%
Year To Date 22.06% 49.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2000 GALLOPING HILL ROAD
-
KENILWORTH,NJ 07033
USA
ph: 908-740-4000
fax: 908-735-1253
investor_relations@merck.com http://www.merck.com
 
 • General Corporate Information   
Officers
Robert M. Davis - Chief Executive Officer and President
Kenneth C. Frazier - Executive Chairman
Caroline Litchfield - Executive Vice President and Chief Financial Offic
Rita A. Karachun - Senior Vice President
Mary Ellen Coe - Director

Peer Information
Merck & Co., Inc. (AGN.)
Merck & Co., Inc. (ABBV)
Merck & Co., Inc. (NVO)
Merck & Co., Inc. (LLY)
Merck & Co., Inc. (RHHBY)
Merck & Co., Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 58933Y105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 2,528.80
Most Recent Split Date: 2.00 (2.00:1)
Beta: 0.37
Market Capitalization: $236,569.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.95%
Current Fiscal Quarter EPS Consensus Estimate: $1.68 Indicated Annual Dividend: $2.76
Current Fiscal Year EPS Consensus Estimate: $7.31 Payout Ratio: 0.39
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: -0.06
Estmated Long-Term EPS Growth Rate: 10.13% Last Dividend Paid: 03/14/2022 - $0.69
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 12.79
Trailing 12 Months: 13.36
PEG Ratio: 1.26
Price Ratios
Price/Book: 5.77
Price/Cash Flow: 12.78
Price / Sales: 4.38
EPS Growth
vs. Year Ago Period: 52.86%
vs. Previous Quarter: 18.89%
Sales Growth
vs. Year Ago Period: 31.63%
vs. Previous Quarter: 17.60%
ROE
03/31/22 - 47.86
12/31/21 - 47.24
09/30/21 - 48.21
ROA
03/31/22 - 17.92
12/31/21 - 16.70
09/30/21 - 16.00
Current Ratio
03/31/22 - 1.40
12/31/21 - 1.27
09/30/21 - 1.31
Quick Ratio
03/31/22 - 1.14
12/31/21 - 1.02
09/30/21 - 1.07
Operating Margin
03/31/22 - 32.91
12/31/21 - 31.68
09/30/21 - 29.84
Net Margin
03/31/22 - 26.27
12/31/21 - 26.02
09/30/21 - 14.64
Pre-Tax Margin
03/31/22 - 29.18
12/31/21 - 28.50
09/30/21 - 13.32
Book Value
03/31/22 - 16.20
12/31/21 - 15.14
09/30/21 - 14.17
Inventory Turnover
03/31/22 - 2.77
12/31/21 - 2.32
09/30/21 - 2.48
Debt-to-Equity
03/31/22 - 0.75
12/31/21 - 0.80
09/30/21 - 0.64
Debt-to-Capital
03/31/22 - 42.75
12/31/21 - 44.51
09/30/21 - 38.98
 

Powered by Zacks Investment Research ©